Figure 1 Cardiac and renal biosynthesis and

Slides:

Advertisements

Similar presentations

Isoenzymes. Role of cofactors and coenzyme vitamins in the catalytic action of enzymes.

Advertisements

Nad metabolites The pyridine dinucleotide, NAD+, is a substrate of sirtuins and coenzyme for hydride transfer enzymes and other NAD+-dependent ADP ribose.

Arch Intern Med. 2004;164(7): doi: /archinte Figure Legend:

Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).

Overview of Pyridine Nucleotides Review Series

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Absorption, transport and metabolism of niacin

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 Role of the kidney in glucose homeostasis

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Nat. Rev. Endocrinol. doi: /nrendo

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 The network of chronic diseases and their mutual influences

NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus Carles Cantó, Keir J. Menzies, Johan Auwerx

Figure 1 The burden of chronic kidney disease (CKD)

Figure 2 Metabolic reprogramming of immune cells upon activation

Figure 1 Metabolic adaptations of cancer cells

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 Model of changes in the serum levels

Figure 2 Roles of mTOR complexes in the kidney

Volume 13, Issue 9, Pages (September 2005)

Why NAD+ Declines during Aging: It’s Destroyed

Figure 2 The potential effects of nicotinamide adenine

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Differentiation and functional control of T-cell subsets

Axon Degeneration: Too Much NMN Is Actually Bad?

Figure 5 Pathways leading to the NAD+ production

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Sirtuin and metabolic kidney disease

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

Figure 4 Differential protective effects of hydration

Figure 1 The insulin signalling pathway

Nat. Rev. Nephrol. doi: /nrneph

Vitamins and Aging: Pathways to NAD+ Synthesis

Nat. Rev. Nephrol. doi: /nrneph

Ng Shyh-Chang, George Q. Daley Cell Metabolism

Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans Pawel.

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

FIGURE Reduced nicotinamide adenine dinucleotide (NADH) is a strong reducing agent and energy currency.

Figure 6 Cross-compartmental junctions in cellular NAD+ metabolism

Figure 1 CD36 structure and post-translational modifications

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Endocrinol. doi: /nrendo

Figure 1 NETosis pathways and potential therapeutic targets

A ‘complexity’ of urate transporters

NAD utilization in Pasteurellaceae.

Nat. Rev. Nephrol. doi: /nrneph

The salvage/recycling pathway for NAD+ biosynthesis from nicotinamide riboside (NR) in manNR, taken in to the body, can be converted to nicotinamide mononucleotide.

Metabolic pathway alterations in PCT

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 1 Oxidative phosphorylation

Nat. Rev. Endocrinol. doi: /nrendo

Neuron-Astrocyte Interactions: Partnership for Normal Function and Disease in the Central Nervous System Eduardo E. Benarroch, MD Mayo Clinic Proceedings

Nat. Rev. Nephrol. doi: /nrneph

Volume 93, Issue 6, Pages e5 (March 2017)

Therapeutic strategies targeting NAMPT against stroke.

Novel targets for mitochondrial medicine

Volume 6, Issue 1, Pages (January 2013)

Volume 129, Issue 3, Pages (May 2007)

Tomohiro Tanaka, Yo-ichi Nabeshima Cell Metabolism

Presentation transcript:

Figure 1 Cardiac and renal biosynthesis and the metabolome of nicotinamide adenine dinucleotide (NAD+) Figure 1 | Cardiac and renal biosynthesis and the metabolome of nicotinamide adenine dinucleotide (NAD+). Two routes of NAD+ synthesis — deamidated (de novo synthesis) and amidated (precursor salvage) — occur in the heart (parts a,c) and the kidney (parts b,d) (Ref. 8). In the amidated route, which dominates in both tissues, the activities of nicotinamide riboside kinase (NRK) isoforms (NRK2 in the heart and NRK1 in the kidney) enable generation of nicotinamide mononucleotide (NMN) from the salvage of nicotinamide riboside (NR), whereas nicotinamide phosphoribosyltransferase (NAMPT) activity converts salvaged nicotinamide (NAM) to NMN. Nicotinamide mononucleotide adenyltransferase (NMNAT) isoforms 1 (nuclear) and 3 (mitochondrial) convert NMN to NAD+ in the amidated route and nicotinic acid mononucleotide (NaMN) to nicotinic acid dinucleotide (NaAD) in the deamidated route. The activities of NMNAT1/3 in the amidated route are much greater in the kidney (part b) than in the heart (part a), as indicated by the arrow thicknesses. Nicotinic acid (NA) can also be converted to an intermediate in the deamidated route, and the activity of NAD synthase (NADS) enables conversion of NaAD to NAD+, although the role of NADS in the heart is speculative. Uptake of NAD+ and its precursors occurs through many means in the heart (part c) and kidney (part d). NAD+ can be directly transported into the heart by the connexion 43 hemichannel (Cx43). Renal uptake of NA occurs through the sodium monocarboxylate transporter (SMCT) (Ref. 14). NR and NMN require NRK1 for optimal uptake and conversion to NAD+ in the kidney20. NRK2 might serve this role for these NAD+ precursors in the heart. Additionally, extracellular NMN might be converted into NR by membrane bound cluster of differentiation 73 (CD73) (Ref. 19) and subsequently taken up by renal NRK1 or cardiac NRK2. Renal NAM uptake is thought to occur through an unidentified transporter14. NAM — generated from exogenous sources or other NAD+ precursors such as NA — is maintained at low levels in the heart and kidney9 through its conversion into the byproducts 1-methylnicotinamide (MeNAM) and N-methyl-4-pyridone-5-carboxamide (Me4PY), which are excreted by the cell. 5′-ectonucleotidase; MCT, monocarboxylate transporter; NADH, reduced NAD. Hershberger, K. A. et al. (2017) Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.5